Symbols / REPL Stock $2.42 -15.09% Replimune Group, Inc.
REPL (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-13 | down | Cantor Fitzgerald | Overweight → Neutral | — |
| 2026-04-13 | down | Leerink Partners | Outperform → Market Perform | $2 |
| 2026-04-13 | down | JP Morgan | Neutral → Underweight | — |
| 2026-04-13 | down | Wedbush | Outperform → Neutral | $2 |
| 2026-04-13 | down | Jefferies | Buy → Hold | $2 |
| 2026-04-13 | down | HC Wainwright & Co. | Buy → Sell | — |
| 2026-02-05 | main | Piper Sandler | Overweight → Overweight | $14 |
| 2026-02-04 | main | Wedbush | Outperform → Outperform | $19 |
| 2025-11-03 | up | BMO Capital | Underperform → Market Perform | $11 |
| 2025-10-27 | up | HC Wainwright & Co. | Neutral → Buy | $12 |
| 2025-10-20 | up | JP Morgan | Underweight → Neutral | $11 |
| 2025-10-20 | up | Leerink Partners | Market Perform → Outperform | $13 |
| 2025-10-20 | up | Wedbush | Neutral → Outperform | $18 |
| 2025-09-19 | down | JP Morgan | Neutral → Underweight | — |
| 2025-09-08 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-07-30 | up | Cantor Fitzgerald | Neutral → Overweight | — |
| 2025-07-23 | down | BMO Capital | Outperform → Underperform | $2 |
| 2025-07-23 | down | Barclays | Overweight → Equal-Weight | $3 |
| 2025-07-23 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-07-22 | down | Leerink Partners | Outperform → Market Perform | $3 |
- REPL stock on track for worst drop in nearly 7 months ahead of FDA decision on skin cancer drug - MSN Sun, 26 Apr 2026 11
- REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits Fri, 10 Apr 2026 07
- REPL Stock Collapses As FDA Rejection Triggers Downgrades - StocksToTrade Sun, 26 Apr 2026 02
- $REPL stock is up 19% today. Here's what we see in our data. - Quiver Quantitative Wed, 22 Apr 2026 14
- FDA setback for Replimune melanoma drug forces job cuts - Stock Titan Fri, 10 Apr 2026 07
- Replimune lead drug rejected by FDA again (REPL:NASDAQ) - Seeking Alpha Fri, 10 Apr 2026 07
- REPL Stock Collapses As FDA Rejects RP1 Melanoma Bid - timothysykes.com Sat, 25 Apr 2026 14
- Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes - Zacks Investment Research Mon, 13 Apr 2026 15
- REPL stock rallies in anticipation of FDA decision on skin cancer drug - MSN Sun, 26 Apr 2026 07
- REPL Stock Collapses As FDA Rejects RP1 Melanoma Bid - StocksToTrade Sun, 26 Apr 2026 03
- REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug - Stocktwits Wed, 08 Apr 2026 07
- REPL Stock Collapses After FDA Rejection And Legal Scrutiny - timothysykes.com Fri, 24 Apr 2026 15
- $REPL stock is down 20% today. Here's what we see in our data. - Quiver Quantitative Fri, 10 Apr 2026 19
- REPL Stock Collapses As FDA Rejection Triggers Downgrades And Probes - StocksToTrade Fri, 24 Apr 2026 18
- REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits Mon, 13 Apr 2026 10
Insider Transactions
Financials
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
259.85
+11.60%
|
232.85
+33.70%
|
174.17
+51.26%
|
115.14
|
| Research And Development |
|
189.45
+8.28%
|
174.96
+38.28%
|
126.53
+59.06%
|
79.55
|
| Selling General And Administration |
|
72.18
+20.68%
|
59.81
+18.31%
|
50.55
+30.40%
|
38.77
|
| Other Operating Expenses |
|
-1.77
+7.66%
|
-1.92
+34.11%
|
-2.91
+8.08%
|
-3.17
|
| Total Expenses |
|
259.85
+11.60%
|
232.85
+33.70%
|
174.17
+51.26%
|
115.14
|
| Operating Income |
|
-259.85
-11.60%
|
-232.85
-33.70%
|
-174.17
-51.26%
|
-115.14
|
| Total Operating Income As Reported |
|
-261.63
-11.44%
|
-234.77
-32.58%
|
-177.08
-49.67%
|
-118.31
|
| EBITDA |
|
-235.43
-14.25%
|
-206.07
-23.11%
|
-167.39
-47.26%
|
-113.67
|
| Normalized EBITDA |
|
-256.55
-11.82%
|
-229.43
-29.33%
|
-177.40
-55.53%
|
-114.06
|
| Reconciled Depreciation |
|
3.50
+31.90%
|
2.65
+8.50%
|
2.45
+13.97%
|
2.15
|
| EBIT |
|
-238.94
-14.47%
|
-208.73
-22.90%
|
-169.84
-46.65%
|
-115.81
|
| Total Unusual Items |
|
21.12
-9.57%
|
23.36
+133.42%
|
10.01
+2465.64%
|
0.39
|
| Total Unusual Items Excluding Goodwill |
|
21.12
-9.57%
|
23.36
+133.42%
|
10.01
+2465.64%
|
0.39
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-247.30
-14.60%
|
-215.79
-23.82%
|
-174.28
-47.65%
|
-118.04
|
| Pretax Income |
|
-246.83
-14.60%
|
-215.39
-23.79%
|
-174.00
-47.41%
|
-118.04
|
| Net Non Operating Interest Income Expense |
|
-7.89
-18.51%
|
-6.66
-60.10%
|
-4.16
-87.13%
|
-2.22
|
| Interest Expense Non Operating |
|
7.89
+18.51%
|
6.66
+60.10%
|
4.16
+87.13%
|
2.22
|
| Net Interest Income |
|
-7.89
-18.51%
|
-6.66
-60.10%
|
-4.16
-87.13%
|
-2.22
|
| Interest Expense |
|
7.89
+18.51%
|
6.66
+60.10%
|
4.16
+87.13%
|
2.22
|
| Other Income Expense |
|
20.92
-13.30%
|
24.13
+457.21%
|
4.33
+747.23%
|
-0.67
|
| Other Non Operating Income Expenses |
|
-0.20
-126.20%
|
0.77
+113.58%
|
-5.68
-435.98%
|
-1.06
|
| Gain On Sale Of Security |
|
21.12
-9.57%
|
23.36
+133.42%
|
10.01
+2465.64%
|
0.39
|
| Tax Provision |
|
0.47
+14.71%
|
0.41
+41.67%
|
0.29
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+10400.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
4.44
-9.57%
|
4.90
+24409.09%
|
0.02
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-247.30
-14.60%
|
-215.79
-23.82%
|
-174.28
-47.65%
|
-118.04
|
| Net Income From Continuing Operation Net Minority Interest |
|
-247.30
-14.60%
|
-215.79
-23.82%
|
-174.28
-47.65%
|
-118.04
|
| Net Income From Continuing And Discontinued Operation |
|
-247.30
-14.60%
|
-215.79
-23.82%
|
-174.28
-47.65%
|
-118.04
|
| Net Income Continuous Operations |
|
-247.30
-14.60%
|
-215.79
-23.82%
|
-174.28
-47.65%
|
-118.04
|
| Normalized Income |
|
-263.98
-12.69%
|
-234.25
-27.12%
|
-184.27
-55.60%
|
-118.43
|
| Net Income Common Stockholders |
|
-247.30
-14.60%
|
-215.79
-23.82%
|
-174.28
-47.65%
|
-118.04
|
| Diluted EPS |
|
-3.07
+5.25%
|
-3.24
-8.36%
|
-2.99
-32.30%
|
-2.26
|
| Basic EPS |
|
-3.07
+5.25%
|
-3.24
-8.36%
|
-2.99
-32.30%
|
-2.26
|
| Basic Average Shares |
|
80.56
+21.02%
|
66.57
+14.36%
|
58.21
+11.49%
|
52.21
|
| Diluted Average Shares |
|
80.56
+21.02%
|
66.57
+14.36%
|
58.21
+11.49%
|
52.21
|
| Diluted NI Availto Com Stockholders |
|
-247.30
-14.60%
|
-215.79
-23.82%
|
-174.28
-47.65%
|
-118.04
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets |
|
551.33
+13.04%
|
487.72
-24.57%
|
646.59
+40.20%
|
461.19
|
| Current Assets |
|
495.88
+14.35%
|
433.67
-26.82%
|
592.60
+46.69%
|
403.98
|
| Cash Cash Equivalents And Short Term Investments |
|
483.80
+15.01%
|
420.67
-27.89%
|
583.39
+47.45%
|
395.65
|
| Cash And Cash Equivalents |
|
111.12
+49.24%
|
74.46
-49.21%
|
146.59
+38.36%
|
105.95
|
| Cash Equivalents |
|
89.90
+118.73%
|
41.10
|
—
|
—
|
| Cash Financial |
|
21.22
-36.39%
|
33.36
|
—
|
—
|
| Other Short Term Investments |
|
372.69
+7.65%
|
346.21
-20.74%
|
436.80
+50.77%
|
289.71
|
| Receivables |
|
3.73
-24.32%
|
4.92
+67.47%
|
2.94
-3.80%
|
3.06
|
| Other Receivables |
|
3.73
-24.32%
|
4.92
+67.47%
|
2.94
-3.80%
|
3.06
|
| Prepaid Assets |
|
—
|
—
|
—
|
5.27
|
| Other Current Assets |
|
8.35
+3.39%
|
8.08
+28.66%
|
6.28
+19.19%
|
5.27
|
| Total Non Current Assets |
|
55.45
+2.58%
|
54.05
+0.12%
|
53.99
-5.64%
|
57.22
|
| Net PPE |
|
52.55
+0.36%
|
52.35
+0.01%
|
52.35
-5.81%
|
55.58
|
| Gross PPE |
|
65.94
+5.93%
|
62.25
+4.46%
|
59.59
-1.29%
|
60.37
|
| Accumulated Depreciation |
|
-13.40
-35.38%
|
-9.90
-36.66%
|
-7.24
-51.03%
|
-4.79
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
22.98
+32.27%
|
17.38
+42.06%
|
12.23
+18.48%
|
10.32
|
| Construction In Progress |
|
1.65
+47.72%
|
1.12
+42.66%
|
0.78
-51.64%
|
1.62
|
| Other Properties |
|
38.81
-7.32%
|
41.87
-6.69%
|
44.87
-5.82%
|
47.65
|
| Leases |
|
2.50
+32.77%
|
1.89
+10.55%
|
1.71
+117.32%
|
0.79
|
| Other Non Current Assets |
|
2.90
+70.76%
|
1.70
+3.91%
|
1.64
+0.00%
|
1.64
|
| Total Liabilities Net Minority Interest |
|
135.49
+19.67%
|
113.21
+24.00%
|
91.30
+82.73%
|
49.96
|
| Current Liabilities |
|
62.36
+54.22%
|
40.44
+19.55%
|
33.83
+62.96%
|
20.76
|
| Payables And Accrued Expenses |
|
32.23
+66.80%
|
19.32
+12.57%
|
17.16
+67.71%
|
10.23
|
| Payables |
|
12.46
+383.44%
|
2.58
-51.94%
|
5.36
+43.73%
|
3.73
|
| Accounts Payable |
|
12.46
+383.44%
|
2.58
-51.94%
|
5.36
+43.73%
|
3.73
|
| Current Accrued Expenses |
|
19.77
+18.05%
|
16.75
+41.89%
|
11.80
+81.47%
|
6.50
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
20.08
+44.40%
|
13.91
+40.34%
|
9.91
+77.93%
|
5.57
|
| Current Debt And Capital Lease Obligation |
|
3.98
+2.68%
|
3.88
+3.25%
|
3.76
+3.44%
|
3.63
|
| Current Capital Lease Obligation |
|
3.98
+2.68%
|
3.88
+3.25%
|
3.76
+3.44%
|
3.63
|
| Other Current Liabilities |
|
6.07
+82.25%
|
3.33
+11.22%
|
2.99
+126.82%
|
1.32
|
| Total Non Current Liabilities Net Minority Interest |
|
73.12
+0.48%
|
72.78
+26.62%
|
57.47
+96.78%
|
29.21
|
| Long Term Debt And Capital Lease Obligation |
|
72.18
+0.27%
|
71.99
+26.29%
|
57.00
+95.17%
|
29.21
|
| Long Term Debt |
|
46.38
+3.50%
|
44.81
+56.41%
|
28.65
|
—
|
| Long Term Capital Lease Obligation |
|
25.80
-5.06%
|
27.18
-4.14%
|
28.35
-2.92%
|
29.21
|
| Other Non Current Liabilities |
|
0.94
+19.72%
|
0.79
+66.53%
|
0.47
|
—
|
| Stockholders Equity |
|
415.84
+11.04%
|
374.51
-32.56%
|
555.29
+35.03%
|
411.23
|
| Common Stock Equity |
|
415.84
+11.04%
|
374.51
-32.56%
|
555.29
+35.03%
|
411.23
|
| Capital Stock |
|
0.08
+26.23%
|
0.06
+7.02%
|
0.06
+21.28%
|
0.05
|
| Common Stock |
|
0.08
+26.23%
|
0.06
+7.02%
|
0.06
+21.28%
|
0.05
|
| Share Issued |
|
77.09
+25.51%
|
61.42
+8.36%
|
56.68
+19.73%
|
47.34
|
| Ordinary Shares Number |
|
77.09
+25.51%
|
61.42
+8.36%
|
56.68
+19.73%
|
47.34
|
| Additional Paid In Capital |
|
1,358.90
+26.90%
|
1,070.87
+3.47%
|
1,034.99
+43.08%
|
723.36
|
| Retained Earnings |
|
-948.58
-35.26%
|
-701.28
-44.45%
|
-485.49
-56.00%
|
-311.20
|
| Gains Losses Not Affecting Retained Earnings |
|
5.45
+12.21%
|
4.86
-15.26%
|
5.73
+688.80%
|
-0.97
|
| Other Equity Adjustments |
|
5.45
+12.21%
|
4.86
-15.26%
|
5.73
+688.80%
|
-0.97
|
| Total Equity Gross Minority Interest |
|
415.84
+11.04%
|
374.51
-32.56%
|
555.29
+35.03%
|
411.23
|
| Total Capitalization |
|
462.22
+10.23%
|
419.32
-28.19%
|
583.94
+42.00%
|
411.23
|
| Working Capital |
|
433.52
+10.25%
|
393.23
-29.63%
|
558.78
+45.81%
|
383.22
|
| Invested Capital |
|
462.22
+10.23%
|
419.32
-28.19%
|
583.94
+42.00%
|
411.23
|
| Total Debt |
|
76.17
+0.39%
|
75.87
+24.87%
|
60.76
+85.02%
|
32.84
|
| Capital Lease Obligations |
|
29.79
-4.10%
|
31.06
-3.27%
|
32.11
-2.22%
|
32.84
|
| Net Tangible Assets |
|
415.84
+11.04%
|
374.51
-32.56%
|
555.29
+35.03%
|
411.23
|
| Tangible Book Value |
|
415.84
+11.04%
|
374.51
-32.56%
|
555.29
+35.03%
|
411.23
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-192.25
-3.66%
|
-185.47
-44.84%
|
-128.05
-55.82%
|
-82.18
|
| Cash Flow From Continuing Operating Activities |
|
-192.25
-3.66%
|
-185.47
-44.84%
|
-128.05
-55.82%
|
-82.18
|
| Net Income From Continuing Operations |
|
-247.30
-14.60%
|
-215.79
-23.82%
|
-174.28
-47.65%
|
-118.04
|
| Depreciation Amortization Depletion |
|
3.50
+31.90%
|
2.65
+8.50%
|
2.45
+13.97%
|
2.15
|
| Depreciation And Amortization |
|
3.50
+31.90%
|
2.65
+8.50%
|
2.45
+13.97%
|
2.15
|
| Other Non Cash Items |
|
4.68
+11.30%
|
4.20
+33.59%
|
3.15
+24.54%
|
2.53
|
| Stock Based Compensation |
|
35.04
+2.69%
|
34.12
+21.31%
|
28.13
+15.98%
|
24.25
|
| Operating Gains Losses |
|
-0.20
+73.93%
|
-0.77
-113.58%
|
5.68
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.20
+73.93%
|
-0.77
-113.58%
|
5.68
|
0.00
|
| Change In Working Capital |
|
20.97
+759.43%
|
2.44
-80.43%
|
12.47
+164.89%
|
4.71
|
| Change In Receivables |
|
1.30
+168.01%
|
-1.92
-3040.98%
|
-0.06
+75.30%
|
-0.25
|
| Change In Prepaid Assets |
|
-0.25
+85.83%
|
-1.78
-67.89%
|
-1.06
-29.94%
|
-0.81
|
| Change In Payables And Accrued Expense |
|
21.68
+236.71%
|
6.44
-51.79%
|
13.36
+128.60%
|
5.84
|
| Change In Accrued Expense |
|
11.74
+27.17%
|
9.23
-18.83%
|
11.38
+140.76%
|
4.72
|
| Change In Payable |
|
9.94
+455.80%
|
-2.79
-241.04%
|
1.98
+77.19%
|
1.12
|
| Change In Account Payable |
|
9.94
+455.80%
|
-2.79
-241.04%
|
1.98
+77.19%
|
1.12
|
| Change In Other Current Assets |
|
-1.20
|
0.00
-100.00%
|
2.65
+4.99%
|
2.53
|
| Change In Other Current Liabilities |
|
-0.56
-84.64%
|
-0.31
-230.77%
|
0.23
+420.55%
|
-0.07
|
| Investing Cash Flow |
|
-23.80
-124.48%
|
97.20
+168.21%
|
-142.50
-7790.48%
|
-1.81
|
| Cash Flow From Continuing Investing Activities |
|
-23.80
-124.48%
|
97.20
+168.21%
|
-142.50
-7790.48%
|
-1.81
|
| Net PPE Purchase And Sale |
|
-6.69
-18.10%
|
-5.66
-149.43%
|
-2.27
+2.83%
|
-2.34
|
| Purchase Of PPE |
|
-6.69
-18.10%
|
-5.66
-149.43%
|
-2.27
+2.83%
|
-2.34
|
| Capital Expenditure |
|
-6.69
-18.10%
|
-5.66
-149.43%
|
-2.27
+2.83%
|
-2.34
|
| Net Investment Purchase And Sale |
|
-17.11
-116.63%
|
102.86
+173.35%
|
-140.23
-26558.87%
|
0.53
|
| Purchase Of Investment |
|
-403.59
+17.55%
|
-489.52
+16.09%
|
-583.41
-128.14%
|
-255.72
|
| Sale Of Investment |
|
386.48
-34.76%
|
592.38
+33.67%
|
443.18
+72.95%
|
256.25
|
| Financing Cash Flow |
|
252.40
+1450.06%
|
16.28
-94.77%
|
311.30
+4618.14%
|
6.60
|
| Cash Flow From Continuing Financing Activities |
|
252.40
+1450.06%
|
16.28
-94.77%
|
311.30
+4618.14%
|
6.60
|
| Net Issuance Payments Of Debt |
|
-0.60
-104.12%
|
14.52
-47.73%
|
27.79
+10626.14%
|
-0.26
|
| Issuance Of Debt |
|
0.00
-100.00%
|
15.00
-46.72%
|
28.15
|
0.00
|
| Repayment Of Debt |
|
-0.60
-25.84%
|
-0.48
-30.41%
|
-0.36
-38.26%
|
-0.26
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
15.00
-46.72%
|
28.15
|
0.00
|
| Long Term Debt Payments |
|
-0.60
-25.84%
|
-0.48
-30.41%
|
-0.36
-38.26%
|
-0.26
|
| Net Long Term Debt Issuance |
|
-0.60
-104.12%
|
14.52
-47.73%
|
27.79
+10626.14%
|
-0.26
|
| Net Common Stock Issuance |
|
155.73
|
0.00
-100.00%
|
187.29
|
0.00
|
| Proceeds From Stock Option Exercised |
|
97.27
+5429.68%
|
1.76
-98.17%
|
96.22
+1302.24%
|
6.86
|
| Changes In Cash |
|
36.35
+150.50%
|
-71.98
-276.64%
|
40.75
+152.66%
|
-77.39
|
| Effect Of Exchange Rate Changes |
|
0.32
+466.28%
|
-0.09
+21.10%
|
-0.11
-113.33%
|
0.82
|
| Beginning Cash Position |
|
76.16
-48.62%
|
148.23
+37.78%
|
107.58
-41.58%
|
184.15
|
| End Cash Position |
|
112.82
+48.14%
|
76.16
-48.62%
|
148.23
+37.78%
|
107.58
|
| Free Cash Flow |
|
-198.94
-4.09%
|
-191.13
-46.66%
|
-130.32
-54.20%
|
-84.52
|
| Interest Paid Supplemental Data |
|
4.20
+37.91%
|
3.04
+185.55%
|
1.07
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.10
-65.00%
|
0.30
|
0.00
-100.00%
|
0.06
|
| Amortization Of Securities |
|
-8.95
+27.41%
|
-12.33
-118.62%
|
-5.64
-353.96%
|
2.22
|
| Common Stock Issuance |
|
155.73
|
0.00
-100.00%
|
187.29
|
0.00
|
| Issuance Of Capital Stock |
|
155.73
|
0.00
-100.00%
|
187.29
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-13 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-07 View
- 42026-04-06 View
- 42026-02-20 View
- 10-Q2026-02-03 View
- 8-K2026-02-03 View
- 8-K2026-01-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|